Investing Snacks1h
Vertex Vibes: Analysts Crank Up the Heat
Vertex Pharmaceuticals has analysts doing financial backflips as they boost its price targets, with Royal Bank of Canada ...
Fierce Pharma6h
For struggling cell and gene therapy field, Peter Marks' FDA exit adds even more uncertainty
The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...
Scotiabank Remains a Hold on Apellis Pharmaceuticals (APLS)
Scotiabank analyst Greg Harrison maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price target of ...
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Apellis Pharmaceuticals (APLS)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Apellis ...
Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $420.00 Price Target at Royal Bank of Canada
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price boosted by Royal Bank of Canada from $408.00 to $420.00 in a research report sent to investors on Tuesday morning,Benzinga ...